Loading...
Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy
BACKGROUND: A few tau immunotherapies are now in clinical trials with several more likely to be initiated in the near future. A priori, it can be anticipated that an antibody which broadly recognizes various pathological tau aggregates with high affinity would have the ideal therapeutic properties....
Na minha lista:
| Udgivet i: | Mol Neurodegener |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5006503/ https://ncbi.nlm.nih.gov/pubmed/27578006 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13024-016-0126-z |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|